This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TEL AVIV, Israel,
May 16, 2013 /PRNewswire/ --
-Strong Conference Presence to Include Presentations/EducationalEvents Featuring the MGuard™ Embolic Protection Stent-
- Company to Host Conference Call on Thursday, May 23rdto Review MASTER Data -
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a robust schedule of educational events and data presentations at EuroPCR, culminating in the first presentation of 6-month results from the MASTER (
Reperfusion) trial of the Company's MGuard™ Embolic Protection Stent (EPS).
EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) and takes place in
Paris, at the Palais Des Congrès,from
May 21-24, 2013.
Gregg W. Stone M.D., the MASTERstudy chairman and the Director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/
Columbia University Medical Center, said, "In these STEMI patients, embolic protection is an unmet need that is not addressed by current bare metal or drug eluting coronary stents. The clinical evidence supporting the benefits of using the MGuard EPS stent in STEMI patientscontinues to grow. This year's EuroPCR meeting will add important new data underlining the protective benefits of MGuard EPS six months post-procedure."
Inspire MD STEMI Symposium
Thursday, May 23, 201312:00 CET, Room 242AB
The Embolic Protection Stent - Beyond current techniques:
A More Effective Solution in STEMI Primary PCI